PIB TrackerWHO names India's pharmacopoeia a regional centre of excellence
The Indian Pharmacopoeia Commission was recognised by the WHO South-East Asia Regulatory Network as a regional centre of excellence in pharmacovigilance and a technical centre on medicine quality.
What happened
- The Indian Pharmacopoeia Commission was recognised by the WHO South-East Asia Regulatory Network.
- It is named a Regional Centre of Excellence in Pharmacovigilance.
- It is also a Technical Centre in Quality of Medicines.
- Recognition came at SEARN's 10th anniversary meeting in Kathmandu, 4-5 August 2026.
- SEARN was established by the WHO South-East Asia Regional Office in 2016.
For Prelims
- IPC: the Indian Pharmacopoeia Commission, Ghaziabad — sets official standards for drugs in India and runs the Pharmacovigilance Programme of India.
- Pharmacovigilance: detecting, assessing and preventing adverse drug reactions after a medicine reaches the market.
- SEARN: the South-East Asia Regulatory Network, set up by WHO SEARO in 2016; marked its 10th anniversary at Kathmandu.
- The recognition: Regional Centre of Excellence in pharmacovigilance and Technical Centre in quality of medicines.
- Indian Pharmacopoeia: the official book of drug standards, legally recognised under the Drugs and Cosmetics Act, 1940.
- Why it matters: India supplies a large share of the developing world's generic medicines.
For UPSC: A health-diplomacy item. Use it for India as the pharmacy of the developing world, drug regulation and pharmacovigilance, WHO regional cooperation mechanisms, and regulatory capacity as an instrument of soft power.
What it is NOT: This is WHO regional-network recognition of an Indian institution's technical capacity — not WHO certification of Indian drug quality generally.
For Mains
Syllabus: GS2.20 · GS2.13 · Linkage L1
Anchor
The regulator, not just the manufacturer — India's medicine-standards body wins regional standing.
Substantiation (data)
Recognition as a Regional Centre of Excellence in Pharmacovigilance and Technical Centre in Quality of Medicines at SEARN's 10th anniversary meeting in Kathmandu.
Exemplification
SEARN, established by WHO SEARO in 2016, lets neighbouring regulators draw on Indian technical capacity rather than building it separately.
Problematisation
Recognition of the regulator does not by itself resolve periodic quality concerns about Indian pharmaceutical exports; enforcement at the plant level is the harder task.
Way-forward
Strengthen inspection capacity and adverse-event reporting at home while extending training and standards support to regional regulators.
Position
Regulatory credibility is the foundation on which India's pharmaceutical export standing rests.
Deploys into: International institutions + health (GS2.20, GS2.13) · WHO regional cooperation, pharmacovigilance and drug regulation, and India as a generic-medicine supplier.
Ministry of Health & Family Welfare · 2026-08-05 · PRID 2295002 · PIB source ↗